【摘要】 视网膜静脉阻塞继发黄斑水肿(RVO-ME)为一种严重危害视功能的常见眼底表现,原因在于视网膜静脉血栓形成,造成视网膜毛细血管压力升高,导致血-视网膜内外屏障破坏,血管通透性增加,血管内血液成分渗透到血管外。到目前为止,抗血管内皮生长因子、玻璃体内注射曲安奈德及视网膜激光光凝等已经成为治疗RVO-ME的主要方法,但近年来地塞米松玻璃体内植入剂(Ozurdex)逐渐应用于RVO-ME的治疗,其生物可降解缓释特性、能有效提高最佳矫正视力、减少中央视网膜厚度、作用时间长、安全性较好及不良反应相对较少等优点越来越受到青睐。现就Ozurdex的作用机制和药理特性,以及其对RVO-ME的治疗进展进行综述。更多还原

【Abstract】 Macular edema secondary to retinal vein occlusion(RVO-ME) is a common fundus disease that severely impairs visual function, and is caused by retinal vein thrombosis, which increases retinal capillary pressure and damages the internal and external blood-retinal barriers, leading to increase of vascular permeability and blood components penetrating blood vessels to outside. So far, anti-VEGF, intravitreal injection of triamcinolone and retinal laser photocoagulation, etc. have become the main treatment methods for RVO-ME. However, in recent years, dexamethasone intravitreal implants(Ozurdex) have gradually been applied to the treatment of RVO-ME. With the biodegradable sustained-release characteristics, Ozurdex can effectively improve the best corrected visual acuity, reduce the central retinal thickness, and has longer duration of action, more safety and fewer adverse reactions relatively. This article reviews the mechanism of action, pharmacological properties of Ozurdex and its progress in the treatment of RVO-ME.更多还原